Form 4: Catalyst Pharmaceuticals Director Acquires Shares and Stock Units

Catalyst Pharmaceuticals director Donald A. Denkhaus acquired options and restricted stock units on November 21, 2024, increasing his holdings in the company.

Summary

• Donald A. Denkhaus, a director at Catalyst Pharmaceuticals, acquired 23,248 options to purchase common stock at an exercise price of $21.12 on November 21, 2024.
• These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
• Mr. Denkhaus also acquired 2,841 restricted stock units (RSUs) on the same date.
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• Following these transactions, Mr. Denkhaus directly owns 212,179 shares of common stock and 215,020 RSUs.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction by a company director, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedule of the options and RSUs aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have made transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The vesting schedule of the options and RSUs is typical for executive compensation packages in the pharmaceutical industry.
• The acquisition of stock options and RSUs by a director is a common practice to align management's interests with shareholders.
• Similar filings are regularly made by directors and officers of publicly traded companies like Amgen, Biogen, and Gilead Sciences.

Stakeholder Impact

• The acquisition of shares and stock units by a director may be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Catalyst Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, CPRX